Seroatlas · Human Serome Atlas

ADPRHL1

Inactive ADP-ribosyltransferase ARH2

Also known as: ARH2, ARHL1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8NDY3
Gene: ADPRHL1
Ensembl: ENSG00000153531
Chromosome: 13
Canonical length: 354 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoli,Plasma membrane

OverviewNCBI Gene

ADP-ribosylation is a reversible posttranslational modification used to regulate protein function. ADP-ribosyltransferases (see ART1; MIM 601625) transfer ADP-ribose from NAD+ to the target protein, and ADP-ribosylhydrolases, such as ADPRHL1, reverse the reaction (Glowacki et al., 2002 [PubMed 12070318]).[supplied by OMIM, Mar 2008]

Canonical amino-acid sequenceUniProt

354 residues, UniProt reviewed canonical sequence.

>Q8NDY3|ADPRHL1
     1  MEKFKAAMLL GSVGDALGYR NVCKENSTVG MKIQEELQRS GGLDHLVLSP GEWPVSDNTI
    61  MHIATAEALT TDYWCLDDLY REMVRCYVEI VEKLPERRPD PATIEGCAQL KPNNYLLAWH
   121  TPFNEKGSGF GAATKAMCIG LRYWKPERLE TLIEVSVECG RMTHNHPTGF LGSLCTALFV
   181  SFAAQGKPLV QWGRDMLRAV PLAEEYCRKT IRHTAEYQEH WFYFEAKWQF YLEERKISKD
   241  SENKAIFPDN YDAEEREKTY RKWSSEGRGG RRGHDAPMIA YDALLAAGNS WTELCHRAMF
   301  HGGESAATGT IAGCLFGLLY GLDLVPKGLY QDLEDKEKLE DLGAALYRLS TEEK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ADPRHL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.21
Highest tissue expression: 274 nTPM

Expression across tissuesHPA

Tissue

heart muscle: 274 nTPM
skeletal muscle: 246 nTPM
tongue: 214 nTPM
fallopian tube: 7.7 nTPM
cerebral cortex: 6.7 nTPM
esophagus: 6.5 nTPM

Single-cell type

thymic myoid cells: 404 nCPM
cardiomyocytes: 187 nCPM
myonuclei: 151 nCPM
myosatellite cells: 28 nCPM
endometrial secretory cells: 28 nCPM
choroid plexus epithelial cells: 26 nCPM

Immune cell

myeloid DC: 0.6 nTPM
memory CD8 T-cell: 0.5 nTPM
MAIT T-cell: 0.4 nTPM
memory B-cell: 0.4 nTPM
classical monocyte: 0.3 nTPM
intermediate monocyte: 0.3 nTPM

Brain region

cerebral cortex: 16 nTPM
choroid plexus: 14 nTPM
thalamus: 12 nTPM
white matter: 12 nTPM
pons: 11 nTPM
basal ganglia: 9.7 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.37
gnomAD pLI: 0
gnomAD missense Z: 0.34
DepMap mean gene effect: -0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

sarcomere

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ADPRHL1 as an antibody target. Whether an autoantibody or antibody against ADPRHL1 could matter depends on whether native ADPRHL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ADPRHL1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ADPRHL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...